Palisade Bio, Inc. (PALI) NASDAQ
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
Address
5800 Armada Drive
Carlsbad, CA 92008
United States of America (the)
Phone
858 704 4900
Website
Sector
Healthcare
Industry
Biotechnology
Employees
8
First IPO Date
March 30, 2007
| Name | Title | Pay | Year Born |
| J. D. Finley | Chief Executive Officer, Chief Financial Officer & Director | 1.01M | 1958 |
| Mitchell Lawrence Jones | President & Chief Medical Officer | 704,000 | 1977 |
| Joerg Heyer | Head of Translational Science & Medicine | 0 | N/A |
| Daniel J. Larkins | Head of Global Regulatory Affairs | 0 | N/A |
| Ramesh C. Donthamsetty | Head of Corporate Development & Investor Relations | 0 | N/A |
| Ryker Willie | Senior Vice President of Finance & Corporate Controller | 0 | N/A |
| Dawn Louro | VP & Head of Clinical Operations | 0 | N/A |
| Sharon Skare | Vice President & Global Head of Clinical Operations | 0 | N/A |
| Adarsh Patel | Head of Chemistry, Manufacturing & Controls | 0 | N/A |
| James Izanec | VP & Head of Clinical Development | 0 | N/A |
Palisade Bio, Inc. is a clinical-stage biopharmaceutical firm dedicated to identifying, advancing, and bringing to market orally administered treatments for significant conditions stemming from a compromised gastrointestinal mucosal barrier. The company's primary therapeutic candidate, LB1148, is an oral liquid formulation designed to inhibit digestive enzymes. Its goal is to safeguard gut integrity when the intestine experiences stress due to factors such as diminished blood supply, infections, or surgical procedures. Established in 2005, the company maintains its headquarters in Carlsbad, California.